Toxocariasis is a human infection with the larvae of roundworms that normally live in dogs and cats. It takes two main forms, and they are treated differently. This article explains how albendazole, the antiparasitic drug most doctors reach for, is used in each form. It covers why treatment of the eye almost always includes a corticosteroid, and how blood tests, especially antibody serology and eosinophil counts, help confirm a diagnosis that can rarely be made by finding the parasite itself. It also sets out where the evidence is solid and where it is thin, so patients and families can have a well-informed conversation with their own physician.
What toxocariasis is and why it behaves differently in people
The culprits are Toxocara canis, the dog roundworm, and Toxocara cati, its feline relative. Infected animals, especially puppies and kittens, shed eggs in their feces. After a few weeks in soil the eggs become infective. A person, most often a small child playing in dirt or a sandbox, swallows an egg, and a larva hatches in the intestine. In the human body the larva cannot complete its life cycle. Instead it wanders through tissues for months, sometimes years, provoking inflammation wherever it settles.
That wandering produces four recognised patterns:
- Visceral larva migrans (VLM): larvae spread through the liver, lungs and other organs. It is classically seen in young children, with fever, cough or wheezing, an enlarged liver and a markedly raised eosinophil count.
- Ocular larva migrans (OLM), or ocular toxocariasis: a larva reaches the eye. Usually only one eye is affected, and often there are no general symptoms at all.
- Covert or common toxocariasis: vague symptoms such as abdominal pain or fatigue, with positive serology.
- Neurotoxocariasis: rare involvement of the brain or spinal cord.
Exposure is common. A large meta-analysis published in PLoS Neglected Tropical Diseases in 2019 estimated that roughly one person in five worldwide carries antibodies to Toxocara. In the United States, national survey data analysed by the Centers for Disease Control and Prevention found seroprevalence of about 14 percent in the late 1980s and early 1990s. Later rounds showed a considerably lower figure, around 5 percent. Most of these people never become noticeably ill. Antibodies show exposure, not necessarily disease.
How albendazole works and what its status is
Albendazole is a synthetic benzimidazole, developed in the 1970s and first used in veterinary medicine. It binds to a parasite protein called beta-tubulin and blocks the assembly of microtubules, the internal scaffolding that worm cells need to absorb nutrients and divide. Human tubulin binds the drug far less avidly. That selectivity is why short courses are generally well tolerated.
Two features of its chemistry matter for toxocariasis. First, albendazole is poorly absorbed on an empty stomach, and a fatty meal increases absorption several-fold. Doctors usually advise taking it with food when the target is in the tissues rather than the gut. Second, the liver converts it to albendazole sulfoxide, the active metabolite. This metabolite reaches the tissues, including the central nervous system and, to a measurable degree, the eye. That tissue penetration is the main reason albendazole has largely replaced older drugs for toxocariasis.
Patients should know that in the United States albendazole is not FDA-approved for toxocariasis. Its labelled indications are neurocysticercosis and hydatid disease. Its use for toxocariasis is off-label, though it is recommended in standard infectious disease and public health guidance and is widely accepted practice. The supporting evidence is modest. The most cited controlled trial is a randomised comparison of albendazole against thiabendazole, published in the Annals of Tropical Medicine and Parasitology in 1989. It found albendazole to be at least as effective and noticeably better tolerated. French investigators in Toulouse have compared other agents, including mebendazole and diethylcarbamazine, in small trials. No large, modern placebo-controlled trial exists. One reason is that many mild cases improve on their own, which makes treatment effects hard to measure.
Treating visceral larva migrans
For visceral disease, the decision to treat depends on how unwell the person is. A child with positive serology, mild eosinophilia and no symptoms may simply be watched, because the larvae eventually die and the immune response settles. When there are symptoms such as fever, wheezing, an enlarged liver or a very high eosinophil count, treatment is usually offered.
The regimen commonly recommended by U.S. public health guidance is albendazole 400 mg twice daily for five days, for both adults and children. Some clinicians dose children by weight. Corticosteroids are not routine in VLM. They are added when inflammation itself threatens an organ, as in severe lung involvement, myocarditis or nervous system disease. In those cases dying larvae can provoke a damaging surge of inflammation, and dampening it protects the organ.
Because larvae in tissue are hard to measure directly, doctors judge response by symptoms and by a gradual fall in the eosinophil count over weeks to months. Antibody levels fall slowly, if at all, so repeat serology is a poor marker of cure.
Treating ocular toxocariasis, and why corticosteroids come first
Eye disease is a different problem. Usually a single larva is involved, and the harm to vision comes less from the worm than from the body's reaction to it. The larva provokes a granuloma, a walled-off nodule of inflammatory cells, in the retina or near the optic nerve. Around it, inflammation clouds the vitreous gel (vitritis) and can lay down scar tissue. That scar tissue may contract, pulling on the retina and causing tractional retinal detachment, macular distortion and permanent loss of vision.
The immune system is well designed to recognise and contain invaders, and eosinophils exist largely to fight parasites. In an organ as delicate as the eye, however, the same defence that walls off a larva can scar tissue that cannot regenerate. That is why corticosteroids are the cornerstone of treating active ocular toxocariasis. Depending on severity they may be given as eye drops, as injections around the eye, or by mouth. Their purpose is to quiet inflammation and limit scarring. A second reason is that killing a larva can briefly intensify inflammation as parasite proteins are released. Giving an antiparasitic drug without steroid cover risks making the eye worse before it gets better.
Whether albendazole adds benefit beyond steroids is genuinely uncertain. The evidence consists of small case series and retrospective reviews, not randomised trials. A small series from Vienna, published in the early 2000s, reported good control of inflammation and few recurrences when albendazole was combined with corticosteroids. Retrospective studies from South Korea, where adult ocular toxocariasis has been linked to eating raw cattle liver, have suggested fewer recurrences with combined treatment than with steroids alone. These are encouraging signals, but they are open to selection bias and cannot prove cause and effect. Ophthalmologists who use albendazole for eye disease often give longer courses than for VLM, commonly two weeks or more and sometimes at higher adult doses. Practice varies, and dosing is individualised.
Some damage needs surgery. Vitrectomy may be used to relieve traction on the retina or to clear persistent opacity. Drug treatment cannot reverse scar tissue that has already formed, which is one reason early assessment by an eye specialist matters.
How serology and eosinophil counts support the diagnosis
Because larvae are microscopic and lodged deep in tissue, doctors almost never see them. Biopsy is rarely appropriate, and stool tests are useless because the worm never matures in the human gut. Diagnosis therefore rests on a combination of clinical picture, exposure history and blood tests.
- Antibody serology (ELISA): the standard test detects antibodies to Toxocara excretory-secretory antigens, proteins the larvae release. For visceral disease, the CDC has reported a sensitivity of about 78 percent and specificity of about 92 percent at its standard cutoff. Some laboratories confirm positive results with a Western blot. The key limitation is that antibodies persist for years, so a positive result cannot by itself distinguish a current illness from an old, harmless exposure.
- Eosinophil count: visceral disease typically produces marked eosinophilia, sometimes with eosinophils making up a large share of all white cells. Total IgE and other antibody levels are often raised as well. Eosinophilia has many causes, including other parasites, allergy and certain drugs, so it supports rather than proves the diagnosis.
- The ocular exception: in eye disease, blood eosinophils are usually normal and serum antibody levels are often low or even negative, because a single larva in a sealed compartment provokes little systemic response. When the diagnosis is uncertain, specialists may test fluid sampled from inside the eye. Comparing antibody levels in eye fluid with those in blood (the Goldmann-Witmer coefficient) can show that antibodies are being produced locally.
One diagnostic point deserves emphasis. In a young child, ocular toxocariasis can cause a white pupillary reflex (leukocoria), the same sign seen in retinoblastoma, a cancer of the eye. Any child with a white pupil in photographs or on examination needs prompt evaluation by an ophthalmologist. Serology helps here, but imaging and expert examination decide.
Safety, pregnancy and prevention
Short courses of albendazole are generally well tolerated. The most common side effects are abdominal discomfort, nausea and headache. Longer courses, such as those sometimes used for eye disease, can raise liver enzymes and, uncommonly, suppress the bone marrow. Physicians typically check a blood count and liver tests when treatment extends beyond a few days.
Pregnancy calls for particular care. Albendazole has caused birth defects and embryonic loss in rats and rabbits. Human data are limited, and the official labelling advises against use in pregnancy. Women who could be pregnant are generally tested beforehand and advised to avoid conception during treatment and for a short period afterward. An unborn child is a patient too. Because toxocariasis is rarely an emergency, treatment can often be postponed, or managed with steroids alone in eye disease, until after delivery. That decision belongs to the mother and her physician together.
Prevention lies largely within a family's own control:
- Deworm puppies and kittens on schedule with a veterinarian, since young animals shed the most eggs.
- Pick up pet waste promptly, before eggs have weeks to mature in the soil.
- Cover sandboxes when not in use.
- Teach children to wash their hands after playing outdoors and handling animals.
- Wash garden produce thoroughly, and avoid raw or undercooked liver.
These are simple habits, and they protect children who are most vulnerable to the eye form of the disease.
Key takeaway: Albendazole is the usual off-label treatment for symptomatic visceral toxocariasis, while eye disease depends first on corticosteroids to control inflammation, and diagnosis rests on serology and eosinophil counts interpreted by a physician who understands their limits.
